Secondary iron overload;Les surcharges en fer secondaires

Revue du Praticien

Volumn 50, Issue 9, 2000, Pages 983-987

  Galactéros, Frédéric ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IRON; IRON CHELATING AGENT; TRANSFERRIN RECEPTOR;

DISEASE DURATION; DRUG EFFICACY; DYSERYTHROPOIESIS; ERYTHROCYTE TRANSFUSION; HEMATOCRIT; HEMATOLOGIC DISEASE; HEMOCHROMATOSIS; HUMAN; IRON ABSORPTION; IRON CHELATION; IRON OVERLOAD; LIFE EXPECTANCY; LONG TERM CARE; PATIENT COMPLIANCE; PHLEBOTOMY; PROGNOSIS; REVIEW;

HUMANS; IRON OVERLOAD;

EID: 17644431316     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Schafer AI, Cheron RG, Dluny R et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981;304:319-24.
2. Gordeuk VR. Hereditary and nutritional iron overload. Baillière's Clin Haemacol 1992;5:169-86.
3. Erlandson ME, Walden R, Stern G, Hilgartner MW, Wehman J, Smith CH, Studies on congenital hemolytic syndromes. IV. Gastrointestinal absorption of iron. Blood 1962;19:359-78.
4. Pippard MJ, Callender ST, Warner GT, Weatherall DJ. Iron absorption and loading in beta-thalassaemia intermedia. Lancet 1979;ii:819-21.
5. Pootrakul P, Kitcharoen, Yansukon P et al. The effect of erythroid hyperplasia on iron balance. Blood 1988;71:1124-9.
6. Raja KB, Simpson RJ, Peters TJ. In vivo studies on the relationship between intestinal iron (Fe3+) absorption, hypoxia and erythropoiesis in the mouse. Br J Haematol 1988;68:373-8.
7. Raja KB, Simpson RJ, Peters TJ. Effect of exchange transfusion of reticulocytes on in vitro and in vivo intestinal iron (fe3+) absorption in mice. Br J Haematol 1989; 73:254-9.
8. Skikne RS, Cook JD. Effect of enhanced erythropoiesis on iron absorption. J Lab Clin Med 1992;20:746-51.
9. Eschbach JW, Cook JD, Scribner BH, Finch CA. Iron balance in hemodialysis patients. Ann Intern Med 1977;87:710-3.
10. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end stage renal disease with recombinant human erythropoietin: results of a combined Phase I and II clinical trial. N Engl J Med 1987;316:73-8.
11. Carzola M, Barosi G, Bergamaschi G et al. Iron loading in congenital dyserythropoietic annemias and congenital sideroblastic annemias. Br. J. Haematol 1983A; 54:649-54.
12. Greiner TC, Burra CP, Dick FR, Henry KM, Mahmood I. Congenital dyserythropoietic anemia type II diagnosed in a 69 year old patient with iron overload. Am J Clin Pathol 1992;98:522-5.
13. Carvill I, Packetes C, Jacobe, Letsky E. Erythropoiesis and the effect of transfusion in homozygous β-thalassemia. N Engl J Med 1978;298:776-8.
14. Zurio MG, Destefano P, Borgna-Pignatti C et al. Survival and causes of death in thalassaemia major. Lancet 1989;i:27-30.
15. Cazzola M, Barosi G, Gobbi PG, Invernizzi R, Ricardi A, Assarie E. Natural history of hipathic refractory sideroblastic anemia. Blood 1998;71:305-12.
16. Irving MG, Halliday JW, Powell LW. Association between alcoholism and increased hepatic iron stores. Alcoholism 1988; 12:7-13.
17. Cohen A, Cohen IJ, Schwartz E. Scurvy and altered iron stores in thalassemia major. N Engl J Med 1981;304:158-60.
18. Lipschitz DA, Bothwell TH, Seftel HC, Wapnick AA, Charlton RW. The role of ascorbic acid in the metabolism of storage iron. Br J Haematol 1971;20:155-63.
19. Roesar HP. The role of ascorbic acid in the turnover of storage iron. Semin Hematol 1983;20:91-100.
20. Montalembert M. La chélation du fer en 1998.Transf Clin Biol 1998;5:353-6.
21. Olivieri NF, Brittenham GM. Iron-chelation therapy and the treatment of thalassemia. Blood 1997;89:739-61.